These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10669338)

  • 1. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).
    Stiehm ER; Fletcher CV; Mofenson LM; Palumbo PE; Kang M; Fenton T; Sapan CV; Meyer WA; Shearer WT; Hawkins E; Fowler MG; Bouquin P; Purdue L; Sloand EM; Nemo GJ; Wara D; Bryson YJ; Starr SE; Petru A; Burchett S
    J Infect Dis; 2000 Feb; 181(2):548-54. PubMed ID: 10669338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA.
    Schüpbach J
    AIDS Rev; 2002; 4(2):83-92. PubMed ID: 12152521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
    Lambert JS; Mofenson LM; Fletcher CV; Moye J; Stiehm ER; Meyer WA; Nemo GJ; Mathieson BJ; Hirsch G; Sapan CV; Cummins LM; Jimenez E; O'Neill E; Kovacs A; Stek A
    J Infect Dis; 1997 Feb; 175(2):283-91. PubMed ID: 9203648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HIV-1 antibody avidity is correlated with clinical status in infected children.
    Sciascia C; Palomba E; Gay V; Tovo PA
    Pediatr AIDS HIV Infect; 1996 Feb; 7(1):14-9. PubMed ID: 11361468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.
    Lathey JL; Tsou J; Brinker K; Hsia K; Meyer WA; Spector SA
    J Infect Dis; 1999 Aug; 180(2):344-50. PubMed ID: 10395848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count, and disease progression in HIV-infected individuals with hemophilia.
    Sabin CA; Lepri AC; Devereux H; Phillips AN; Loveday C; Lee CA
    J Infect Dis; 2001 Aug; 184(4):511-4. PubMed ID: 11471111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study on some systemic humoral and cellular immune markers in only HIV or HIV and hepatitis B infected children.
    Voiculescu C; Bălăşoiu M; Turculeanu A; Filipaş L; Voiculescu M; Georgescu D
    Rom J Virol; 1993; 44(1-2):97-111. PubMed ID: 9702255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Harris DR; Rich K; Meyer WA; Read JS; Moye J; Nugent RP; Korelitz J; Bethel J; Pahwa S
    AIDS; 1999 Jan; 13(1):31-9. PubMed ID: 10207542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection.
    Schacker T; Collier AC; Coombs R; Unadkat JD; Fox I; Alam J; Wang JP; Eggert E; Corey L
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):145-52. PubMed ID: 7749791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression.
    Keoshkerian E; Ashton LJ; Smith DG; Ziegler JB; Kaldor JM; Cooper DA; Stewart GJ; Ffrench RA
    J Med Virol; 2003 Dec; 71(4):483-91. PubMed ID: 14556259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.
    Shearer WT; Israel RJ; Starr S; Fletcher CV; Wara D; Rathore M; Church J; DeVille J; Fenton T; Graham B; Samson P; Staprans S; McNamara J; Moye J; Maddon PJ; Olson WC
    J Infect Dis; 2000 Dec; 182(6):1774-9. PubMed ID: 11069253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
    Mascola JR; Louder MK; VanCott TC; Sapan CV; Lambert JS; Muenz LR; Bunow B; Birx DL; Robb ML
    J Virol; 1997 Oct; 71(10):7198-206. PubMed ID: 9311792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two different preparations of HIV immune globulin for efficiency of neutralization of HIV type 1 primary isolates.
    Nichols CN; Bernal I; Prince AM; Andrus L
    AIDS Res Hum Retroviruses; 2002 Jan; 18(1):49-56. PubMed ID: 11804556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease.
    Sterling TR; Hoover DR; Astemborski J; Vlahov D; Bartlett JG; Schupbach J
    J Infect Dis; 2002 Oct; 186(8):1181-5. PubMed ID: 12355373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternatives to HIV-RNA and CD4 count to monitor HIV disease progression: a prospective cohort study in Romania.
    Kozinetz CA; Matusa R; Ruta S; Hacker CS; Cernescu C; Cazacu A
    J Med Virol; 2005 Oct; 77(2):159-63. PubMed ID: 16121384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.
    Blattner WA; Oursler KA; Cleghorn F; Charurat M; Sill A; Bartholomew C; Jack N; O'Brien T; Edwards J; Tomaras G; Weinhold K; Greenberg M
    J Infect Dis; 2004 May; 189(10):1793-801. PubMed ID: 15122515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antibody production (IVAP) in the follow-up of pediatric human immunodeficiency virus type 1-infected patients.
    Rusconi S; Riva A; Cocchi F; Massironi E; Tornaghi R; de Maddalena C; de Pasquale MP; Galli M
    Pediatr AIDS HIV Infect; 1997 Apr; 8(2):127-9. PubMed ID: 11361779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.